Trends in PCSK9 inhibitor utilization in the United States, Europe, and other countries: An analysis of international sales data

Affiliations

• ¹ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
• ² Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and Political Science, London, UK.
• ³ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China; Research Department of Practice and Policy, UCL School of Pharmacy, London, UK; Laboratory of Data Discovery for Health, Hong Kong SAR, China.
• ⁴ Research Department of Practice and Policy, UCL School of Pharmacy, London, UK; Laboratory of Data Discovery for Health, Hong Kong SAR, China.
• ⁵ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health, Hong Kong SAR, China; The University of Hong Kong Shenzhen Institute of Research and Innovation, Hong Kong SAR, China; Department of Pharmacy, HKU-Shenzhen Hospital, Shenzhen, Guangdong, China. Electronic address: ewchan@hku.hk.